Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/2/2026

Treatment of Non-Cirrhotic Portal Fibrosis (NCPF)

Clinical Presentation and Diagnosis

  • NCPF presents with signs of portal hypertension in the absence of cirrhosis 1
  • Diagnosis requires exclusion of cirrhosis and other causes of non-cirrhotic portal hypertension 2
  • Portal hypertension with patent portal and hepatic veins is a characteristic feature of NCPF 1

Management Approach

1. Management of Variceal Bleeding

  • Endoscopic therapy with band ligation or sclerotherapy is the first-line treatment for acute variceal bleeding 2
  • Endoscopic band ligation is preferable to sclerotherapy due to superior outcomes 2
  • Non-selective beta blockers (NSBBs) should be used for prevention of variceal bleeding, as recommended by the American Association for the Study of Liver Diseases 2, 3
  • NSBBs reduce portal pressure by decreasing cardiac output and causing splanchnic vasoconstriction 3
  • A reduction of hepatic venous pressure gradient by 10-12% with beta blockers protects against variceal bleeding 3

2. Management of Refractory Cases

  • Transjugular Intrahepatic Portosystemic Shunt (TIPS) is considered for uncontrolled bleeding despite endoscopic and pharmacological therapy, with good clinical outcomes in NCPF 2, 4
  • TIPS has shown good control of ascites and 5-year survival of 60-89% in NCPF patients 4
  • However, hepatic encephalopathy rates may be high (>35%) after TIPS 4
  • Combination therapy with NSBBs plus endoscopic band ligation is recommended for secondary prophylaxis (prevention of rebleeding) 5

3. Management of Other Complications

  • Portal vein thrombosis (PVT) has a higher incidence in NCPF compared to cirrhosis, and screening is recommended at least every 6 months 2
  • Early anticoagulation therapy leads to recanalization in 54% of patients with PVT 2

Special Considerations

  • Liver transplantation is considered for patients who develop liver failure or unmanageable portal hypertension-related complications, as recommended by the European Association for the Study of the Liver 2
  • Anticoagulation is considered in patients with NCPF who have underlying prothrombotic conditions or who develop PVT, although this remains debated due to the risk of gastrointestinal bleeding 2

Management of Non-Cirrhotic Portal Fibrosis (NCPF) Bleeding

Initial Management

  • Initiate vasoactive drugs (somatostatin/octreotide or terlipressin) immediately when variceal bleeding is suspected in patients with NCPF, according to the American College of Radiology 6
  • Transfuse red blood cells conservatively in patients with NCPF and variceal bleeding: start when hemoglobin reaches 7 g/dL with goal of 7-9 g/dL, as excessive transfusion paradoxically increases portal pressure, as recommended by the European Association for the Study of the Liver 7

Prevention of Rebleeding

  • Treat bleeding from portal hypertensive gastropathy with portal pressure-lowering measures (NSBBs) rather than hemostatic correction in patients with NCPF, as suggested by the European Association for the Study of the Liver 7
  • Avoid large-volume blood product transfusion as it paradoxically increases portal pressure and worsens bleeding in patients with NCPF, according to the European Association for the Study of the Liver 7
  • Do NOT use tranexamic acid in active variceal bleeding—it is contraindicated and increases thrombotic risk in patients with NCPF, as warned by the European Association for the Study of the Liver 7

Management and Diagnostic Work‑up of Non‑Cirrhotic Portal Fibrosis (NCPF)

Guideline‑Based Management of Portal Hypertension

  • For patients with NCPF who develop portal hypertension, treat complications according to established cirrhosis guidelines, using combined endoscopic therapy and non‑selective β‑blockers as the first‑line strategy for preventing variceal bleeding; screen for pro‑thrombotic disorders and consider anticoagulation in high‑risk individuals. 8

Diagnostic Confirmation

  • Diagnosis requires (1) liver biopsy that demonstrates the absence of cirrhosis, (2) exclusion of other chronic liver diseases (viral hepatitis B/C, NASH/alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson disease, primary biliary cholangitis, congenital hepatic fibrosis, sarcoidosis, schistosomiasis), and (3) demonstration of patent portal and hepatic veins on Doppler ultrasound. 8

Additional Diagnostic Work‑up

  • Approximately 40 % of Western NCPF patients harbor thrombophilic disorders; therefore systematic screening for pro‑thrombotic conditions is recommended. 8
  • Evaluation should also include assessment for immunologic diseases, HIV infection, and exposure to implicated drugs such as azathioprine or didanosine. 8
  • When persistent cholestasis or biliary abnormalities are present, magnetic resonance cholangiography should be performed to detect portal biliopathy. 8

Anticoagulation Strategy

  • Long‑term anticoagulation is indicated in NCPF patients with an underlying myeloproliferative neoplasm. 8
  • Permanent anticoagulation should be considered for individuals with strong pro‑thrombotic conditions or a history suggestive of intestinal ischemia or recurrent thrombosis. 8
  • Management of identified pro‑thrombotic disorders should follow the respective specialty guidelines (e.g., hematology or vascular medicine). 8

Management of Variceal Bleeding and TIPS in Non‑Cirrhotic Portal Fibrosis (NCPF)

Initial Management of Variceal Bleeding

  • Endoscopic band ligation combined with non‑selective beta‑blockers should be used as first‑line therapy for variceal bleeding in NCPF, mirroring the approach for cirrhotic portal hypertension; transjugular intra‑hepatic portosystemic shunt (TIPS) is reserved for refractory cases and covered stents are preferred when TIPS is performed. 9, 10

Indications for TIPS

  • TIPS is recommended when endoscopic and pharmacologic measures fail to control variceal bleeding in NCPF patients. This recommendation is supported by the 2020 Gut guidelines and the 2022 North American recommendations. 9, 11, 10, 12

Technical Considerations for TIPS in NCPF

  • Covered stents should be used for TIPS in NCPF because they provide superior patency compared with bare‑metal stents. 9, 10
  • Patient selection for TIPS in NCPF follows the same criteria as in cirrhosis, with particular attention to risk factors for hepatic encephalopathy. 9, 10

Outcomes and Complications of TIPS

  • In NCPF, TIPS yields 5‑year survival rates of approximately 60 %–89 % and effectively controls ascites. 11
  • Despite preserved liver function, hepatic encephalopathy occurs in more than 35 % of NCPF patients after TIPS. 11

Pre‑TIPS Encephalopathy Screening

  • All elective TIPS candidates should be screened for covert and overt hepatic encephalopathy using at least two of the following tests:
  • Presence of covert hepatic encephalopathy is considered a relative contraindication to elective TIPS. 9, 10

TIPS for Refractory Ascites

  • TIPS may be considered for selected NCPF patients with refractory ascites, although this indication is less common than in cirrhosis. 10

Technical Feasibility and Pitfalls

  • TIPS is technically feasible in NCPF and provides outcomes comparable to or better than those seen in cirrhotic patients; concerns about technical difficulty should not preclude its use. 11
  • The principal concern with TIPS in NCPF is the unexpectedly high rate of hepatic encephalopathy despite preserved hepatic function. 11